论文部分内容阅读
目的 观察来氟米特 (LEF)对激素治疗无效或复发的难治性肾病综合征的疗效及安全性。方法 6 0例难治性肾病综合征患者随机分为两组 ,实验组接受LEF治疗 ,对照组接受霉酚酸酯 (MMF)治疗。观察治疗后 12周及 2 4周的相关临床指标变化 ,并进行评价。结果 治疗 12周后LEF组总有效率为 6 9.9% ,与MMF组疗效无显著性差异 (P >0 .0 5 )。治疗 2 4周 ,LEF组血清白蛋白、2 4h尿蛋白定量均有明显改善 (P <0 .0 5 ) ,LEF组总有效率为 86 .6 % ,两组相比无显著性差异 (P >0 .0 5 )。两组患者均耐受良好。结论 来氟米特能够有效的缓解难治性肾病综合征。
Objective To observe the efficacy and safety of leflunomide (LEF) in patients with refractory nephrotic syndrome, which is ineffective or recurrence of hormone therapy. Methods Sixty patients with refractory nephrotic syndrome were randomly divided into two groups. The experimental group received LEF and the control group received mycophenolate mofetil (MMF). The changes of relevant clinical indexes at 12 weeks and 24 weeks after treatment were observed and evaluated. Results After 12 weeks of treatment, the total effective rate in LEF group was 69.9%, which was not significantly different from that in MMF group (P> 0.05). After 24 weeks of treatment, the levels of serum albumin and 24 hours urinary protein in LEF group were significantly improved (P <0.05), and the total effective rate in LEF group was 86.6%, there was no significant difference between the two groups (P > 0 .0 5). Both groups were well tolerated. Conclusion Leflunomide can effectively alleviate refractory nephrotic syndrome.